HARPOON THERAPEUTICS ANNOUNCES APPOINTMENT OF NATALIE R. SACKS, M.D., AS CHIEF MEDICAL OFFICER South San Francisco, CA – October 3, 2018 – Harpoon Therapeutics, Inc., a clinical-stage immunotherapy company developing a new class of T cell engaging therapeutics,...
UNUM THERAPEUTICS ANNOUNCES ABSTRACT ACCEPTED FOR PRESENTATION AT THE FOURTH CRI-CIMT-EATI-AACR INTERNATIONAL CANCER IMMUNOTHERAPY CONFERENCE – Complete Responses Observed in Three of Six Patients with relapsed or refractory CD20-positive B cell non-Hodgkin...
Aptinyx Initiates Phase 1 Study of NYX-458 Development in Parkinson’s Disease Cognitive Impairment Planned EVANSTON, Ill., Aug. 02, 2018 (GLOBE NEWSWIRE) — Aptinyx Inc. (NASDAQ:APTX), a clinical-stage biopharmaceutical company developing transformative therapies...
Truveris Expands Audit Capabilities with Launch of TruAudit™ Solution allows clients to track PBM performance by implementing several new audits NEW YORK–(BUSINESS WIRE)–Truveris, Inc. today announced new audit capabilities geared towards further...
Deciphera Pharmaceuticals Reports Updated Interim Phase 1 Clinical Study Results with DCC-2618 at The 2018 American Society of Clinical Oncology Annual Meeting (ASCO) and Provides Additional Clinical and Regulatory Updates on DCC-2618 – Initial Objective...
Arvinas and Macroceutics Establish DEL Screening Collaboration on Undruggable Targets NEW HAVEN, Conn. and Monmouth Junction New Jersey, November 21, 2017 – Arvinas LLC, a private biotechnology company creating a new class of drugs based on protein degradation, and...
Recent Comments